Halozyme Therapeutics (HALO) Receivables - Other (2018 - 2024)

Halozyme Therapeutics (HALO) has 7 years of Receivables - Other data on file, last reported at $20.3 million in Q4 2024.

• Receivables - Other for Q4 2024 came in at $20.3 million, up 1930.0% year-over-year; the trailing twelve-month figure through Dec 2024 was $20.3 million (up 1930.0% YoY), and the FY2024 annual result was $20.3 million, up 1930.0% from the prior year.
• Receivables - Other climbed to $20.3 million in Q4 2024 per HALO's latest filing, from $1.0 million in the prior quarter.
• Over five years, Receivables - Other peaked at $69.2 million in Q3 2022 and troughed at $243000.0 in Q2 2023.
• A 5-year average of $20.5 million and a median of $15.1 million in 2022 frame the typical range for Receivables - Other.
• The sharpest annual moves came in 2023 and 2024: Receivables - Other plunged 97.57% in 2023, then jumped 1930.0% in 2024.
• A 5-year view of Receivables - Other shows it stood at $7.0 million in 2020, then surged by 328.57% to $30.0 million in 2021, then surged by 130.56% to $69.2 million in 2022, then slumped by 98.55% to $1.0 million in 2023, then jumped by 1930.0% to $20.3 million in 2024.
• Business Quant data shows HALO's Receivables - Other at $20.3 million in Q4 2024, $1.0 million in Q4 2023, and $3.3 million in Q3 2023.